{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T10:40:45Z","timestamp":1697193645451},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T00:00:00Z","timestamp":1184630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Arsenic trioxide (As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub>) is an effective agent for the treatment of relapsed acute promyelocytic leukemia (APL). We report a patient with intestinal pseudo\u2010obstruction, which occurred while treating relapsed APL with As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub>. A 6\u2010year\u2010old female with relapsed APL developed paralytic ileus, hyperleukocytosis, and a high fever while being treated with As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub>. Although As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> was discontinued and dexamethasone was administered, vomiting and abdominal distension worsened. An ileostomy was performed and diffuse patch\u2010like infiltrations on the bowel surface were noted. Pathologic findings revealed APL cells involving the entire intestinal layers. This case history suggests that As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> when used for reinduction therapy for APL may adversely affect the intestine and cause acute intestinal pseudo\u2010obstruction. Pediatr Blood Cancer 2008;50:872\u2013874. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/pbc.21302","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T19:19:39Z","timestamp":1184699979000},"page":"872-874","source":"Crossref","is-referenced-by-count":0,"title":["Acute intestinal pseudo\u2010obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide"],"prefix":"10.1002","volume":"50","author":[{"given":"Jeong A","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Hyung","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Seop","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,7,17]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371501"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401859"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402719"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3852"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391901"},{"key":"e_1_2_4_7_2","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down regulation of Bcl\u20102 expression and modulation of PML\u2010RAR alpha\/PML proteins","volume":"88","author":"Chen GQ","year":"1996","journal-title":"Blood"},{"key":"e_1_2_4_8_2","first-page":"396a","article-title":"Phase I trial and pharmacokinetic study of arsenic trioxide in children with refractory leukemia","volume":"21","author":"Fox E","year":"2002","journal-title":"ASCO Proc"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2367"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.9.1704.1704"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.5.1701"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-4-292"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92029-X"},{"key":"e_1_2_4_14_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0733-8627(20)30760-4","article-title":"Toxicologic causes of acute abdominal disorders","volume":"7","author":"Muller PD","year":"1989","journal-title":"Emerg Med Clin North Am"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx050106d"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21302","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T03:51:11Z","timestamp":1697082671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,17]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1002\/pbc.21302"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21302","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,17]]}}}